Hem­genix now ap­proved, Paul Per­reault plans his ex­it from CSL; Lian­Bio pres­i­dent hands in res­ig­na­tion

→ As CSL trends up­ward, Paul Per­reault will soon step down, putting one of his lieu­tenants in the top spot.

Paul McKen­zie, the COO at the Aus­tralian phar­ma since 2019, will be­come CSL’s chief ex­ec­u­tive on March 6, while Per­reault lends a hand in an ad­vi­so­ry ca­pac­i­ty for six more months af­ter the tran­si­tion takes ef­fect. McKen­zie owns Big Phar­ma ex­pe­ri­ence from Mer­ck, Bris­tol My­ers Squibb and J&J’s Janssen, and was Bio­gen’s EVP of phar­ma­ceu­ti­cal op­er­a­tions & tech­nol­o­gy be­fore CSL came call­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.